NASDAQ:PVLA Palvella Therapeutics (PVLA) Stock Price, News & Analysis $149.56 -8.57 (-5.42%) Closing price 09/23/2026 04:00 PM EasternExtended Trading$149.57 +0.01 (+0.01%) As of 09/23/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest About Palvella Therapeutics Stock (NASDAQ:PVLA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Palvella Therapeutics alerts:Sign Up Key Stats Today's Range$147.43▼$157.6250-Day Range$124.15▼$158.1352-Week Range$56.54▼$161.38Volume180,598 shsAverage Volume205,560 shsMarket Capitalization$2.16 billionP/E RatioN/ADividend YieldN/APrice Target$209.14Consensus RatingModerate Buy Company Overview Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for patients with rare genetic and dermatologic diseases. The company uses its proprietary QTORIN platform to formulate and deliver medicines locally to affected tissues, with the goal of improving treatment effectiveness while limiting systemic exposure. Palvella’s lead program is QTORIN 3.9% rapamycin, an investigational topical gel being developed for microcystic lymphatic malformations, rare lesions caused by abnormalities in the lymphatic system. The company has also evaluated QTORIN-based rapamycin formulations in other rare skin disorders, including pachyonychia congenita, a painful inherited disease affecting the nails, skin and feet. Based in Wayne, Pennsylvania, Palvella is advancing its pipeline through clinical development and regulatory activities in the United States. The company’s programs are intended to address conditions for which treatment options remain limited, and its strategy is centered on developing targeted therapies for underserved rare-disease populations.AI Generated. May Contain Errors. Read More Palvella Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScorePVLA MarketRank™: Palvella Therapeutics scored higher than 50% of companies evaluated by MarketBeat, and ranked 566th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.1 / 5Analyst RatingModerate Buy Consensus RatingPalvella Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.93, and is based on 1 strong buy rating, 13 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialPalvella Therapeutics has a consensus price target of $209.14, representing about 39.8% upside from its current price of $149.56.Amount of Analyst CoveragePalvella Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Palvella Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Palvella Therapeutics are expected to decrease in the coming year, from ($6.36) to ($8.01) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Palvella Therapeutics is -30.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Palvella Therapeutics is -30.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPalvella Therapeutics has a P/B Ratio of 63.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Palvella Therapeutics' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted19.21% of the float of Palvella Therapeutics has been sold short.Short Interest Ratio / Days to CoverPalvella Therapeutics has a short interest ratio ("days to cover") of 11.14, which indicates bearish sentiment.Change versus previous monthShort interest in Palvella Therapeutics has recently increased by 6.59%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPalvella Therapeutics does not currently pay a dividend.Dividend GrowthPalvella Therapeutics does not have a long track record of dividend growth. News and Social Media3.6 / 5News Sentiment0.80 News SentimentPalvella Therapeutics has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.50 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Palvella Therapeutics this week, compared to 6 articles on an average week.MarketBeat Follows3 people have added Palvella Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership1.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Palvella Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,526,138.00 in company stock.Percentage Held by Insiders17.20% of the stock of Palvella Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions40.11% of the stock of Palvella Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Palvella Therapeutics' insider trading history. Receive PVLA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Palvella Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PVLA Stock News HeadlinesPalvella Therapeutics (NASDAQ:PVLA) COO Sells $654,936.48 in StockSeptember 21 at 4:22 AM | americanbankingnews.comPalvella Therapeutics (NASDAQ:PVLA) COO Kathleen Goin Sells 4,302 Shares of StockSeptember 19, 2026 | insidertrades.comWhy I believe the AI market will split in Q4Matt McCall, who recommended Nvidia near $6 a share, says the AI market is splitting in two - just like the dot-com era split Pets.com from Amazon. One robotics business tied to his research posted $100 million in quarterly revenue, a fifth straight quarter of sequential growth, and 33.4% year-over-year growth. Meanwhile, three hyped names on his avoid list still depend on story over substance. See the full breakdown in his Great AI Shock briefing. | The Oxford Club (Ad)George Jenkins Sells 12,371 Shares of Palvella Therapeutics (NASDAQ:PVLA) StockSeptember 17, 2026 | americanbankingnews.comGeorge Jenkins Sells 13,352 Shares of Palvella Therapeutics (NASDAQ:PVLA) StockSeptember 17, 2026 | americanbankingnews.comPalvella Therapeutics (NASDAQ:PVLA) Director George Jenkins Sells 1,777 SharesSeptember 16, 2026 | insidertrades.comPalvella Therapeutics Inc.: Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical OfficerSeptember 9, 2026 | finanznachrichten.deChristopher Kiritsy Sells 313 Shares of Palvella Therapeutics (NASDAQ:PVLA) StockSeptember 5, 2026 | insidertrades.comSee More Headlines PVLA Stock Analysis - Frequently Asked Questions How have PVLA shares performed this year? Palvella Therapeutics' stock was trading at $104.67 at the beginning of the year. Since then, PVLA stock has increased by 42.9% and is now trading at $149.56. How were Palvella Therapeutics' earnings last quarter? Palvella Therapeutics, Inc. (NASDAQ:PVLA) announced its quarterly earnings data on Tuesday, August, 4th. The company reported ($1.52) earnings per share for the quarter, missing the consensus estimate of ($1.17) by $0.35. Read the conference call transcript. Who are Palvella Therapeutics' major shareholders? Palvella Therapeutics' top institutional shareholders include Montanova Capital LLC (7.88%), BlackRock Inc. (6.37%), First Light Asset Management LLC (5.36%) and Primecap Management Co. CA (1.78%). Insiders that own company stock include George M Jenkins, Elaine J Heron, Kathleen Goin and Christopher P Kiritsy. View institutional ownership trends. How do I buy shares of Palvella Therapeutics? Shares of PVLA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings8/04/2026Today9/23/2026Next Earnings (Estimated)11/10/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (20m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 PVLA's financial health is in the Green zone, according to TradeSmith. PVLA has been in this zone for over 20 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:PVLA Previous SymbolNASDAQ:PVLA CIK1583648 Webwww.palvellatx.com Phone(484) 253-1461Fax49-8161-141-1444Employees29Year Founded2015Price Target and Rating Average Price Target for Palvella Therapeutics$209.14 High Price Target$270.00 Low Price Target$133.00 Potential Upside/Downside+39.8%Consensus RatingModerate Buy Rating Score (0-4)2.93 Research Coverage15 Analysts Profitability EPS (Trailing Twelve Months)($4.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$41.72 million Net MarginsN/A Pretax MarginN/A Return on Equity-47.84% Return on Assets-38.33% Debt Debt-to-Equity RatioN/A Current Ratio21.18 Quick Ratio21.18 Sales & Book Value Annual Sales$42.81 million Price / Sales50.34 Cash FlowN/A Price / Cash FlowN/A Book Value$2.36 per share Price / Book63.37Miscellaneous Outstanding Shares14,410,000Free Float11,930,000Market Cap$2.16 billion OptionableN/A Beta-0.25 Social Links 10 Best Stocks to Own - Fall 2026Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free Report This page (NASDAQ:PVLA) was last updated on 9/24/2026 by MarketBeat.com Staff. From Our PartnersCODE RED: AI Meltdown Imminent?After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...Paradigm Press | SponsoredWhat the Iran War Is Really AboutTwo thousand missiles struck Iran. Three days later, Dylan Jovine sat in two private meetings with U.S. Congre...Behind the Markets | SponsoredHow to get a stake in Anthropic — before the IPOAnthropic, the maker of Claude AI, has reportedly filed for an IPO that could arrive as early as October. Its ...Weiss Ratings | SponsoredAmazon's touch-enabled robot points to AI's next phaseAmazon wants touch-enabled robots to handle 80% of work across roughly 14 billion warehouse items a year. One ...The Oxford Club | SponsoredShocking new footage just releasedGerardo Del Real is calling it the Third Convergence Event, a new catalyst hitting the uranium market that he ...Digest Publishing | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredIf you keep cash in a U.S. bank account… read this NOWSince 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every d...Banyan Hill Publishing | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Palvella Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Palvella Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
